Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Tempus And JW Pharmaceutical Partner for Data-Based Early R&D
Details : The collaboration aims to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : AVA6103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Avacta Group
Deal Size : Undisclosed
Deal Type : Collaboration
Avacta and Tempus Partner to Advance AI-Driven Oncology Drug Development
Details : The collaboration will provide Avacta access to Tempus’ multimodal datasets to characterize the deep biology of the tumor microenvironment and FAP activity for AVA6103 and AVA7100.
Product Name : AVA6103
Product Type : Peptide
Upfront Cash : Undisclosed
October 21, 2024
Lead Product(s) : AVA6103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Avacta Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus Expands Collaboration with Takeda for Multimodal Oncology Research
Details : The collaboration seeks to leverage Tempus' multimodal real-world datasets and biological modeling capabilities to enhance Takeda’s pipeline of cancer therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus Announces Real World Data Collaboration with BioNTech
Details : The collaboration leverages Tempus' robust multimodal datasets, analytical support and computational biology expertise in support of BioNTech’s next-generation oncology pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 09, 2024
Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development
Details : Through the collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $70.0 million
Deal Type : Expanded Collaboration
GSK Announces Expanded Collaboration With Tempus In Precision Medicine To Accelerate R&D
Details : GSK and Tempus currently collaborate on an open label phase II study, which applies an innovative, data-driven approach designed to accelerate and streamline study timelines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $70.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kartos Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
Details : Kartos is collaborating with Tempus to use the xT assay, a 648-gene panel, to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may benefit from treatment with KRT-232 (navtemadlin, a small molecule MDM2 inhibitor).
Product Name : KRT-232
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kartos Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics
Details : The strategic collaboration aims to optimize Tempus’ AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novellus
Deal Size : Undisclosed
Deal Type : Collaboration
Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
Details : Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas.
Product Name : PLX-8394
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novellus
Deal Size : Undisclosed
Deal Type : Collaboration